InvestorsHub Logo

dadbrotheroftwins

04/14/21 4:25 PM

#158931 RE: B52T38 #158925

Exactly! "If safe, and shows potential benefit" don't people understand? The safety is beyond question, I believe that the CD10 study showed it is safer than placebo, as it perhaps improved some of the patients underlying conditions. The SAE was less with leronlimab than with placebo, go figure. It should be obvious that it has potential benefit, as 82% of the critical over 65 improved vs placebo. EUA NOW!!! imo

humble howard

04/14/21 5:52 PM

#158949 RE: B52T38 #158925

You and I and everyone else feel it should be enough. My god, what more proof do they need, but apparently the FDA feels differently or NP isn't telling us the whole story. He does have a history of leaving a few things out.